Oscar Health focuses on technology-driven health insurance through ACA exchanges. In June 2025, its stock reached $22.09, bolstered by strong Q1 earnings reporting $3.05 billion revenue, a 42% increase year-over-year. However, the stock fell 39% following Centene’s withdrawal of guidance, raising concerns about recoverability due to regulatory risks and enrollment declines. Analysts' cautious outlook reflects a consensus price target of $12.42, influenced by subsidy expirations and rising costs associated with less healthy enrollees within ACA exchanges.
Oscar Health (NYSE:OSCR) specializes in technology-driven health insurance for individuals and small groups, focusing on Affordable Care Act exchanges and utilizing AI for enhanced member experience.
In June 2025, OSCR's stock peaked at $22.09 after reporting $3.05 billion in revenue, a 42% year-over-year increase, along with earnings beating expectations.
Following Centene's withdrawal of its 2025 guidance, OSCR's stock plummeted 39%, making recovery prospects uncertain due to regulatory risks and rising healthcare costs.
Analysts project a consensus one-year price target of $12.42 for OSCR, with concerns over ACA subsidy expiration and potential declines in enrollment impacting its future.
Collection
[
|
...
]